Millendo Therapeutics

Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.